期刊文献+

罗格列酮治疗2型糖尿病肾病的临床应用

Luo the Geleg alkone treats 2 diabetes nephrosis clinical practice
原文传递
导出
摘要 目的:评价罗格列酮对2型糖尿病肾病的治疗效果.方法:回顾性收集62例2型糖尿病合并糖尿病肾病患者治疗方法和治疗结果.结果:治疗后治疗组和对照组的FBG、PBG、HbAlc、2 hBG相比差异无统计学意义,两组药物降血糖效果无明显差异.治疗组显效10例,有效15例,无效6例,临床总有效率81%;对照组显效5例,有效13例,无效13例,临床总有效率58%.治疗组疗效明显优于对照组.结论:罗格列酮治疗2型糖尿病肾病,整体效果较好,可起到改善肾功能的作用,对延缓早期DN的进一步发展具有重要意义. Objective:Appraises Luo the Geleg alkone to 2 diabetes nephrosis treatment result. Methods: Review collection 62 example 2 diabetes merge diabetes nephrosis patient method of treatment and treatment result. Results: After the treatment treats the group and control group's FBG, PBG,HbAIc,2 hBG compares the difference non-statistics significance,two groups of medicines fall the blood sugar effect not obvious difference. The treatment group shows results 10 examples,effective 15 examples,invalid 6 examples,clinical total effectiveness 81% lThe control group shows results 5 examples, effective 13 examples,invalid 13 examples, clinical total effectiveness 58 %. The treatment group curative effect surpasses the control group obviously. Conclusion:Luo the Geleg alkone treats 2 diabetes nephrosis, the overall effect is good, may play the improvement kidney function role,to delays early DN the further development to have the vital significance.
出处 《按摩与康复医学》 2010年第24期52-52,共1页 Chinese Manipulation and Rehabilitation Medicine
关键词 罗格列酮 2型糖尿病 肾病 治疗 Luo Geleg alkone 2 diabetes Nephrosis Treatment
  • 相关文献

参考文献4

二级参考文献42

  • 1[1]Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator-activated receptor γ-ligands inhibit development of atherosclerosis in LDL receptor-dificient mice. J Clin Invest,2000,106:523-531. 被引量:1
  • 2[2]Minamikava J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab,1998,83:1818-1820. 被引量:1
  • 3[3]Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care,2001,24:683-689. 被引量:1
  • 4[4]Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type Ⅱdiabetes. Diabetes,1996,45:1661-1669. 被引量:1
  • 5[5]Yang C, Chang TJ, Chang JC, et al. Rosiglitazone(BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-kinase pathway. Diabetes,2001,50:2598-2602. 被引量:1
  • 6[6]Oakes ND, Thalén PG, Jacinto SM, et al. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes,2001,50:1158-1165. 被引量:1
  • 7[7]Murakami K, Tobe K, Ide T, et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma:effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats . Diabetes,1998,47:1841-1847. 被引量:1
  • 8[8]Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: A potential mechanism of insulin sensitization. Endocrinology,2002,143:998-1007. 被引量:1
  • 9[9]Walker AB, Chattington PD, Buckingham RE, et al. The thiazolidinedione rosiglitazone(BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes,1999,48:1448-1453. 被引量:1
  • 10[10]Nordt TK, Peter K, Bode C, et al. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. J Clin Endocrinol Metab,2000,85:1563-1568. 被引量:1

共引文献86

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部